CHOSA Oncology AB payback of convertible loan in process - update
CHOSA Oncology AB has as previously announced initiated the process of payback of the convertible loan of 14,98 mSEK (plus interest) SEK which RhoVac obtained from shareholders to support the development of RV001. The process is unfortunately more complex than anticipated, which causes a delay. There have been many questions about the calculation of the interest and below is a clarification.The original loan was 24.979.760 SEK, and a partial refund of 10.000.000 SEK was paid back on August 29[th], 2022. The interest rent is 10% and CHOSA will pay 5 months of interest on the full amount and